DigitalOcean Holdings Inc vs Heron Therapeutics Inc — how do they compare? DigitalOcean Holdings Inc trades at $122 (market cap $15.25B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: DigitalOcean Holdings Inc is far larger — about 240.5× Heron Therapeutics Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| DOCN | HRTX | |
|---|---|---|
Market Cap | $15.25B | $63.41M |
Sector | Technology | Health |
52-Week High | $181.29 | $1.49 |
52-Week Low | $29.99 | $0.32 |
Enterprise Value | $16.02B | $161.31M |
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $124.15, up 1.57% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with 29% revenue growth driven by AI demand, and raised full-year guidance. Valuation ratios are elevated, with a P/E of 56.43 and P/S of 13.99, reflecting high growth expectations. Analyst consensus is bullish with a $173.71 price target, though net cash flow turned negative in 2025 due to investing activities.
Outlook is positive given accelerating AI-driven revenue growth and profitability, but risks include high debt levels, competitive cloud market pressures, and stretched valuations. The stock offers upside if execution continues, but investors face volatility from earnings sensitivity and macroeconomic headwinds.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →